CagriSema
Also known as: cagrisema
CagriSema is Novo Nordisk's investigational once-weekly fixed-dose co-formulation of cagrilintide 2.4 mg (long-acting amylin analog) with semaglutide 2.4 mg (GLP-1 receptor agonist) for chronic weight management. Unlike the other grey-market blends, it has a proper Phase 3 clinical program. Novo Nordisk filed an FDA NDA in December 2025; as of April 2026 it is under FDA review and not yet approved.
Pricing for CagriSema
Live vendor pricing, normalized to $/mg so sizes compare fairly — fused with each seller's Merit trust score and latest independent COA purity. Prices refresh daily.
COAs for CagriSema
5 third-party tests across 3 vendors. Each card links to the full report.
For
CagriSema
by Simple Peptide· batch 02-21101-02905-P
For
CagriSema
by Simple Peptide· batch CGSM09032025-J
For
CagriSema
by Profound Aminos· batch 2025-04-31
For
CagriSema
by Hydro Research Peptides· batch 2024-08-05
For
CagriSema
by Profound Aminos· batch cmojb7ss001e3kirxyi4q8sbq
27 citations indexed for CagriSema
review · 2026
Cagrilintide and CagriSema for weight reduction and metabolic risk modification in overweight or obesity: a systematic review and meta-analysis
Background Obesity is a global health challenge associated with substantial cardiometabolic morbidity. Cagrilintide, a long-acting amylin analogue, alone or in combination with semaglutide (CagriSema), has emerged as a novel pharmacologic strategy for weight management.
cohort · 2026
Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta-Analysis of Randomized Clinical Trials
Background Obesity is a chronic, progressive disease affecting over 1 billion adults worldwide, linked to serious comorbidities, including diabetes, hypertension, and cardiovascular disease and associated with increased mortality. Achieving clinically meaningful weight loss is critical to reducing cardiometabolic risk.
meta-analysis · 2026
Novel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A Network Meta-Analysis
Background Long-acting amylin-based therapies (ABTs) are emerging anti-obesity agents; we sought to compare their effects on weight and anthropometric outcomes in adults with overweight/obesity without diabetes, evaluate gastrointestinal (GI) safety, and rank agents and doses within a network meta-analysis (NMA) framew…
meta-analysis · 2026
Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression
Background Obesity is a complex chronic disease requiring effective long-term management. We performed a systematic review and meta-analysis to evaluate the efficacy and safety of cagrisema and cagrilintide monotherapy compared with semaglutide in individuals with obesity.
meta-analysis · 2026
CagriSema Versus Semaglutide Monotherapy or Placebo for Obesity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with GRADE Assessment
The obesity epidemic is a major health burden that enhances susceptibility to a broad spectrum of metabolic-associated comorbidities, ranging from fatty liver disease and endocrine dysfunction to traditional risks like type 2 diabetes mellitus and cardiovascular disease.
rct · 2026
CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1
Background Fixed-dose combination of semaglutide/cagrilintide (CagriSema 2.4 mg/2.4 mg) has demonstrated significant and clinically relevant body weight reductions in adults with overweight or obesity compared with placebo.